How miRecule’s Rio Biofarma partnership could advance extrahepatic RNA delivery
miRecule and Rio Biofarma are pairing peptide delivery with RNA payloads, but clinical validation and scalable manufacturing remain ahead.
Pharma & Biotech
Pharma & Biotech
FDA approves Sanofi’s Sarclisa Escena with wearable injector for multiple myeloma
The United States Food and Drug Administration (FDA) has approved Sanofi’s Sarclisa Escena for subcutaneous administration through the CirCLIQ on-body injector, creating the first FDA-authorised anticancer treatment that can be delivered using a wearable injector. The regulator approved the fixed 1,400-milligram dose on July 9, 2026 for several multiple myeloma treatment combinations already supported by
Features & Analysis
Can Sanofi’s CirCLIQ strategy change how anti-CD38 therapies reach patients?
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Pharma & Biotech
Could Sanofi’s Sarclisa SC approval change how Japan treats multiple myeloma?
Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!
Pharma & Biotech
Why Sanofi’s Tzield expansion changes the treatment window for type 1 diabetes
Discover how Sanofi’s Tzield approval could reshape newly diagnosed pediatric type 1 diabetes care and why major clinical questions remain.
Pharma & Biotech
Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus
Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.
Pharma & Biotech
Can Sanofi’s venglustat priority review change the treatment outlook for type 3 Gaucher disease?
Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.
Pharma & Biotech
Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs
CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.
Pharma & Biotech
Could LANGLARA finally crack the high-cost insulin access problem in the United States?
Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.
Pharma & Biotech
Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes
FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.